Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (NYSE: CLVT) will report fourth quarter and full year 2025 results before the market opens on Tuesday, February 24, 2026. The company will publish a press release and earnings supplement and host a live conference call and webcast at 9:00 AM ET.
The live webcast and audio broadcast will be available via Clarivate investor relations and a replay will be posted two hours after the call and remain available for one year.
Clarivate (NYSE: CLVT) announced Clarivate Nexus, an academic assistant that embeds library content and services into AI tools, web environments, and campus systems to reconnect students and researchers with trusted scholarly resources.
Core features include unified library access, full-text linking from AI outputs, source verification and citation support, literature recommendations, and surfaced library services. Nexus will launch as a browser extension with a planned early access release in Q3 2026 and later support direct campus integrations. The product emphasizes entitlement-aware access, user privacy, and library branding, and is built on Clarivate indexes including Web of Science and ProQuest collections.
Clarivate (NYSE:CLVT) published the 15th Top 100 Global Innovators list on January 21, 2026, highlighting organizations that lead high-strength invention activity.
The 2026 report finds that the Top 100 account for 16% of the world’s strongest AI inventions, AI filings have doubled repeatedly since 2019 with over one million invention specifications published by mid-2025, and Samsung Electronics retains the #1 rank. Japan leads with 32 organizations on the list; the United States lists 18 organizations overall but holds only one of the top 10 positions. Six new entrants and six re-entrants are named, and 16 organizations are all-time recipients.
MongoDB (NASDAQ: MDB) expanded its AI capabilities on Jan 15, 2026 by integrating Voyage AI embedding and reranking models into MongoDB Atlas and Community deployments to enable production-ready retrieval tasks without moving data.
Key launches include five Voyage 4 embedding models (voyage-4, voyage-4-large, voyage-4-lite, voyage-4-nano, and multimodal-3.5), Automated Embedding for MongoDB Vector Search (public preview), Atlas embedding and reranking APIs, and an AI assistant for Compass and Atlas Data Explorer. MongoDB said these features aim to reduce latency, simplify architectures, and improve retrieval accuracy for customers (60,000+ users).
Clarivate (NYSE: CLVT) released its Drugs to Watch 2026 report on January 6, 2026, identifying eleven therapies that may reach blockbuster status or transform care within five years (blockbuster defined as ≥USD 1 billion annual sales).
The report covers advances across metabolic disease, oncology, immunology, rare conditions and protein degraders, cites over 160 analysts reviewing hundreds of drugs using ten AI-enhanced datasets, and highlights delivery innovation and Mainland China as a growing commercial and innovation force.
Clarivate (NYSE: CLVT) announced that Nissan Motor Co. (7201.T) has selected IPfolio, Clarivate's intellectual property management software, to modernize Nissan's IP operations.
The implementation will provide advanced workflow automation, customized workflows, improved data visibility, and API integration to enable scalable IP management, better portfolio control, and enhanced protection of intellectual property.
Clarivate (NYSE:CLVT) on December 4, 2025 launched the Cortellis Regulatory Intelligence AI Assistant, an agentic AI tool now available to all Cortellis Regulatory Intelligence customers.
The assistant provides instant, cited, context-aware answers; multilingual support; rapid document summarization; and draft-versus-final guidance comparison to speed regulatory review and decision making. Developed with customer feedback and built on Clarivate's existing AI platform, the product targets life sciences regulatory teams and aims to improve accuracy and workflow efficiency across the product lifecycle.
Clarivate (NYSE: CLVT) launched Derwent Patent Monitor on November 24, 2025 to streamline IP and R&D patent reviews and accelerate decisions on patentability, freedom to operate (FTO), opposition and assertion.
The cloud solution uses AI-powered threat analysis built on proprietary Derwent World Patents Index data — including 67m+ invention summaries authored by 850+ Clarivate experts — to surface critical risks and speed first-pass reviews. The product is purpose-built for collaboration with structured project reviews and real-time feedback to reduce reliance on scattered emails and spreadsheets and help patent teams align more quickly.
Clarivate (NYSE: CLVT) said CEO Matt Shem Tov and EVP/CFO Jonathan Collins will present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference on Wednesday, November 19, 2025 at 1:20 pm ET.
The presentation will be live-webcast at https://kvgo.com/rbc-2025-global-tech/clarivate-november-2025, with a replay available on the company investor site https://ir.clarivate.com for 90 days after the event.
Clarivate (NYSE: CLVT) released its Companies to Watch: Rediscovering Women's Health report on November 13, 2025, spotlighting seven startups advancing therapies and research across reproductive care, chronic disease and mental health.
The report cites persistent underinvestment—women's health receives 15% of venture capital and 5% of global healthcare R&D funding—and highlights clinical-stage programs and financing momentum for named companies including Daré Bioscience, Freya Biosciences, Gesynta Pharma, Granata Bio, Hope Medicine, Oxolife and Reunion Neurosciences.
Methodology relied on Clarivate proprietary sources (Cortellis deals, clinical, regulatory and competitive intelligence) to assess proof of concept, milestones, collaborations, capital raised and intellectual property.